9,447 results match your criteria Psoriatic Arthritis


Early arthritis clinic is effective for rheumatoid and psoriatic arthritides.

Authors:
M K Nisar

Rheumatol Int 2019 Feb 19. Epub 2019 Feb 19.

Rheumatology Department, Luton and Dunstable University Hospital NHSFT, Lewsey Road, Luton, LU4 0DZ, UK.

Introduction: Early arthritis clinics (EACs) have been well established since 1980s. Most of the data for their effectiveness comes from rheumatoid arthritis (RA) management and is largely limited to process outcomes. There is little evidence that such clinics improve clinical outcomes particularly for psoriatic arthritis (PsA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-019-04253-4DOI Listing
February 2019

Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.

PLoS One 2019 19;14(2):e0212043. Epub 2019 Feb 19.

Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network, Toronto, ON, Canada.

Psoriasis and its associated inflammatory arthritis, psoriatic arthritis (PsA), have a clear heritable component, but a large proportion of the heritable risk remains unexplained by gene sequence variation. This study aimed to determine if epigenetic factors contribute to the missing heritability in psoriatic disease. DNA methylation profiling was performed on sperm cells from 23 probands with psoriasis without PsA (PsC), 13 PsA probands, and 18 unaffected controls. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212043PLOS
February 2019
1 Read

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.

Indian Dermatol Online J 2019 Jan-Feb;10(1):1-12

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_437_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739PMC
February 2019

Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting.

Patient Prefer Adherence 2019 22;13:187-194. Epub 2019 Jan 22.

Bristol-Myers Squibb, Roma, Italy.

Purpose: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA).

Patients And Methods: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Units was performed. Patients ≥18 years with a hospitalization discharge diagnosis of PsA (International Classification of Diseases, Ninth Revision code: 696. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PPA.S178603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348972PMC
January 2019

Clinical significance and immunobiology of IL-21 in autoimmunity.

J Autoimmun 2019 Feb 14. Epub 2019 Feb 14.

Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, PR China. Electronic address:

Interleukin-21 (IL-21), an autocrine cytokine predominantly produced by follicular helper T (Tfh) and T helper 17 (Th17) cells, has been proven to play an important role in the immune system, for example, by promoting proliferation and the development of Tfh and Th17 cells, balancing helper T cell subsets, inducing B cell generation and differentiation into plasma cells, and enhancing the production of immunoglobulin. These effects are mainly mediated by activation of the JAK/STAT, MAPK and PI3K pathways. Some IL-21 target genes, such as B lymphocyte induced maturation protein-1 (Blimp-1), suppressor of cytokine signaling (SOCS), CXCR5 and Bcl-6, play important roles in the immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2019.01.013DOI Listing
February 2019
1 Read

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

J Am Acad Dermatol 2019 Feb 7. Epub 2019 Feb 7.

Baylor Scott and White, Dallas, Texas.

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.11.058DOI Listing
February 2019
1 Read

A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real life setting: data from the Leeds Combined Psoriatic Service.

J Am Acad Dermatol 2019 Feb 13. Epub 2019 Feb 13.

NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.014DOI Listing
February 2019
1 Read

Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients-immune-related candidate proteins affected by TNF blocking treatment.

Arthritis Res Ther 2019 Feb 15;21(1):60. Epub 2019 Feb 15.

Rheumatology Unit, Department of Medicine, Solna, Center of Molecular Medicine (CMM), Karolinska Institutet, Karolinska University Hospital, SE-17176, Stockholm, Sweden.

Background: Signs of inflammation in cerebrospinal fluid (CSF) of rheumatoid arthritis patients correlate positively with fatigue, a central nervous system (CNS)-related symptom that can be partially suppressed by TNF blockade. This suggests a possible role for CNS inflammation in arthritis that may be affected by TNF blockade. We therefore investigated the effects of TNF blockade on the arthritis CSF proteome and how candidate proteins related to clinical measures of disease activity and inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1846-6DOI Listing
February 2019
2 Reads

Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

From Internal Medicine - Rheumatology, University of California at San Diego, La Jolla, California; Department of Internal Medicine - Rheumatology, Cleveland Clinic, Cleveland, Ohio; Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania; Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Janssen Research & Development LLC funded this study. Janssen Biotech Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, manufactures golimumab. Authors who are employees of the study sponsor were involved in the study design, collecting and analyzing the data, and interpreting the results. Writing support was provided by Janssen Scientific Affairs LLC. Janssen Research & Development LLC approved the content of the article; the authors made the decision to submit for publication. Drs. Harrison and Hsia, and L. Kim, K.H. Lo, and L. Noonan are employees of Janssen Research & Development LLC and own stock or stock options in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly owned subsidiary. A. Kavanaugh, MD, Internal Medicine - Rheumatology, University of California at San Diego; M.E. Husni, MD, MPH, Internal Medicine - Rheumatology, Cleveland Clinic; D.D. Harrison, MD, MPH, Immunology, Janssen Research & Development LLC; L. Kim, PhD, Immunology, Janssen Research & Development LLC; K.H. Lo, PhD, Immunology, Janssen Research & Development LLC; L. Noonan, RT(MR), Immunology, Janssen Research & Development LLC; E.C. Hsia, MD, MSCE, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania. Address correspondence to Dr. E.C. Hsia, Janssen Research & Development LLC, 1400 McKean Road, PO Box 776, Spring House, Pennsylvania 19477, USA. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication October 18, 2018.

Objective: Evaluate effects of intravenous (IV) golimumab (GOL) on radiographic progression in psoriatic arthritis (PsA).

Methods: This phase III, randomized, double-blind, placebo-controlled trial (GO-VIBRANT) randomized patients with active PsA to receive IV placebo (n = 239) or IV GOL 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20. Radiographic progression (controlled secondary endpoint) was evaluated as change from baseline at Week 24 in PsA-modified total Sharp/van der Heijde scores (SvdH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180681DOI Listing
February 2019

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report.

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore University of Leeds, Leeds, UK, and University of Oxford, Oxford, UK Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada. Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital & Department of Rheumatology, Odense University Hospital, Denmark Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre, , Amsterdam, The Netherlands. Department of Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada Pfizer Inc., Montreal, QC, Canada Department of Rheumatology, St Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Ireland. Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada Patient Research Partner; Division of Rheumatology, Duke University School of Medicine, Durham, NC; Kezar Life Sciences, South San Francisco, CA, USA Division of Rheumatology, Duke University School of Medicine, Durham, NC, USA Royal Prince Alfred Hospital Medical Centre, Sydney, Australia Patient Research Partner, employed by Amgen Inc, Thousand Oaks, CA, USA Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, Ottawa, ON, Canada Swedish-Providence-St. John's Health Systems and University of Washington, Seattle, WA, USA Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Ottawa Hospital Research Institute, and School of Epidemiology and Public Health, University of Ottawa, ON, Canada Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA St. Vincent's University Hospital and University College Dublin, Dublin, Ireland Royal National Hospital for Rheumatic Diseases and the University of Bath, Bath, UK. Address correspondence to Alexis Ogdie, MD, University of Pennsylvania, White Building Room 5023, 3400 Spruce St, Philadelphia, Pennsylvania 19104, United States. E-mail:

Objective: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181089DOI Listing
February 2019
1 Read
3.187 Impact Factor

Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World.

J Rheumatol 2019 Feb 15. Epub 2019 Feb 15.

From the Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University; Institute of Rheumatology, Tokyo Women's Medical University; Department of Orthopedic Surgery, Juntendo University School of Medicine; Division of Rheumatology, Department of Rheumatology, Keio University School of Medicine, Tokyo; Department of Orthopedic Surgery, Shiga University of Medical Science, Shiga; Department of Rheumatology, Tonan Hospital, Hokkaido; Department of Orthopedic Surgery, Fujita Health University, Aichi; Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo; Department of Rheumatology, Chubu Rosai Hospital, Aichi; Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi; Department of Orthopedics, Osaka Minami Medical Center, Osaka; Department of Rheumatology, Daido Hospital, Aichi; Department of Internal Medicine, Juntendo University Koshigaya Hospital, Saitama; Department of Orthopedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan; departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA; Division of Rheumatology, National University Hospital, Singapore; Division of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea; Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan; Hospital Universitario Reina Sofía/IMIBIC/University of Córdoba, Córdoba, Spain; Department of Rheumatology, Paris Descartes University, Cochin Hospital, Paris, France; INSERM Unit 1183, CRESS, Paris, France; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. This study was conducted under the umbrella of the International Society for Spondyloarthritis Assessment (ASAS) and the COMOSPA study was supported by the unrestricted grants from Pfizer, AbbVie, and UCB. M.K. received honoraria from AbbVie and Ayumi; K.Y. receives tuition support from Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer, and PhRMA); A.M. has received research grants from Abbvie, Pfizer, and MSD. M. Kishimoto, MD, Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University; K. Yoshida, MD, MPH, ScD, Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health; N. Ichikawa, MD, Institute of Rheumatology, Tokyo Women's Medical University; H. Inoue, MD, Department of Orthopedic Surgery, Juntendo University School of Medicine; Y. Kaneko, MD, Division of Rheumatology, Department of Rheumatology, Keio University School of Medicine; T. Kawasaki, MD, Department of Orthopedic Surgery, Shiga University of Medical Science; K. Matsui, MD, Department of Rheumatology, Tonan Hospital, M. Morita, MD, Department of Orthopedic Surgery, Fujita Health University; M. Suda, MD, Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University; K. Tada, MD, Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine; N. Takizawa, MD, Department of Rheumatology, Chubu Rosai Hospital; N. Tamura, MD, Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine; A. Taniguchi, MD, Institute of Rheumatology, Tokyo Women's Medical University; Y. Taniguchi, MD, Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School; S. Tsuji, MD, Department of Orthopedics, Osaka Minami Medical Center; Y. Haji, MD, Department of Rheumatology, Daido Hospital; R. Rokutanda, MD, Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University; H. Yanaoka, MD, Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University; P.P. Cheung, MD, Division of Rheumatology, National University Hospital; J. Gu, MD, Division of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University; T.H. Kim, MD, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; S.F. Luo, MD, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University; C. López Medina, MD, Hospital Universitario Reina Sofía/IMIBIC/University of Córdoba; A. Molto, MD, Department of Rheumatology, Paris Descartes University, Cochin Hospital, and INSERM Unit 1183, CRESS; M. Dougados, MD, Department of Rheumatology, Paris Descartes University, Cochin Hospital, and INSERM Unit 1183, CRESS; S. Kobayashi, MD, PhD, Department of Internal Medicine, Juntendo University Koshigaya Hospital; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center; T. Tomita, MD, Department of Orthopedic Biomaterial Science, Osaka University Graduate School of Medicine. Address correspondence to Dr. M. Kishimoto, Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University, 9-1 Akashicho, Chuo-ku, Tokyo, Japan, 104-8560. E-mail: Accepted for publication October 11, 2018.

Objective: To delineate clinical characteristics of patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world.

Methods: Using the ASAS-COMOSPA (Assessment of Spondyloarthritis international Society-COMOrbidities in SPondyloArthritis) data, an international cross-sectional observational study of patients with SpA, we analyzed information on demographics, disease characteristics, comorbidities, and risk factors. Patients were classified by region: Japan, other Asian countries (China, Singapore, South Korea, Taiwan), and non-Asian countries (Europe, the Americas, Africa). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180412DOI Listing
February 2019
1 Read
3.187 Impact Factor

Reproductive health outcomes in women with psoriatic arthritis.

Ann Rheum Dis 2019 Feb 15. Epub 2019 Feb 15.

EULAR Centre For Arthritis And Rheumatic Diseases, Dublin Academic Medical Centre, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214790DOI Listing
February 2019
1 Read

Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Rheumatology Unit, University of Bari, Italy.

Objectives: To determine the incidence of serious infections (SIs) among the spondyloarthropathy (SpA) patients from the "Gruppo Italiano per lo Studio delle Early Arthritis" (GISEA) registry and treated with tumour necrosis factor (TNF) inhibitors (TNFIs), and to identify the factors associated with the development of the infections.

Methods: This observational study on 3321 GISEA-registered SpA patients collected real-world demographic and clinical data relating to their biological drug treatments. The overall incidence of infections was analysed by type of SpA. Read More

View Article

Download full-text PDF

Source
February 2019
2 Reads

What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Internal Medicine, Division of Rheumatology, University of Ottawa Faculty of Medicine, Ottawa Hospital Research Institute, Canada.

Objectives: Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO).The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA+ or MDA-).

Methods: PsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry. Read More

View Article

Download full-text PDF

Source
February 2019
4 Reads

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Int J Rheum Dis 2019 Feb 14. Epub 2019 Feb 14.

Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.

Objectives: To evaluate the transition from reference infliximab Remicade to biosimilar Remsima in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

Methods: Patients were informed through a letter about the transition to a biosimilar and were subsequently contacted for possible additional questions and whether they agreed upon the transition. Once agreed, Remsima was administered at the same dosage and interval as previous treatment with Remicade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13512DOI Listing
February 2019
1 Read

Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.

J Clin Pharm Ther 2019 Feb 14. Epub 2019 Feb 14.

Turkish Medicines and Medical Devices Agency, Ministry of Health, Ankara, Turkey.

What Is Known And Objective: Anti-tumour necrosis factor-alpha (anti-TNF-α) therapy is known to raise the risk of granulomatous infections, leading to development of risk management strategies at national or global level. This study aimed to determine the relative risk (RR) of tuberculosis (TB) due to anti-TNF-α usage in patients with rheumatologic diseases (RDs) in a nationwide basis.

Method: This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without anti-TNF-α agents, as registered in the national prescription information system between years 2013 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.12814DOI Listing
February 2019
1 Read

Skin inflammation associated with arthritis, synovitis and enthesitis. Part 2: rheumatoid arthritis, reactive arthritis, Reiter's syndrome, Lyme borreliosis, dermatomyositis and lupus erythematosus.

J Dtsch Dermatol Ges 2019 Feb;17(2):167-181

Department of Rheumatology and clinical Immunology, Freiburg University Medical Center, Medical Faculty, Albert Ludwigs University, Freiburg, Germany.

Syndromes associated with concurrent skin and joint inflammation frequently pose a therapeutic challenge for both dermatologists and rheumatologists. In part 1 of this review, we discussed psoriatic arthritis as well as the autoinflammatory disorders SAPHO syndrome, Still's disease and Behçet's disease. Part 2 will address rheumatoid arthritis, reactive arthritis, Reiter's syndrome and Lyme borreliosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13761DOI Listing
February 2019
1 Read

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial.

J Intern Med 2019 Feb 14. Epub 2019 Feb 14.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo.

Background And Objectives: The 52-week, randomized, double blind, non-inferiority, government funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with infliximab originator. The NOR-SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT-P13 throughout the 78-week study period (maintenance group) vs patients switched to CT-P13 at week 52 (switch group).

Primary Outcome: disease worsening during follow-up based on disease specific composite measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.12880DOI Listing
February 2019
1 Read

Inflammasome Signaling and Impaired Vascular Health in Psoriasis.

Arterioscler Thromb Vasc Biol 2019 Feb 14:ATVBAHA118312246. Epub 2019 Feb 14.

From the Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine (M.S.G., E.A.F., J.S.B.).

Objective- Psoriasis is an inflammatory skin disease which heightens the risk of cardiovascular disease. This study directly investigated vascular endothelial health and systemically altered pathways in psoriasis and matched controls. Approach and Results- Twenty patients (mean age, 40 years; 50% male) with active psoriasis and 10 age-, sex-matched controls were recruited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.118.312246DOI Listing
February 2019
1 Read

Efficacy and safety of secukinumab in a psoriatic patient affected by comorbid metabolic disorders.

Dermatol Ther 2019 Feb 13:e12858. Epub 2019 Feb 13.

Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12858DOI Listing
February 2019
1 Read

Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years.

Clin Rheumatol 2019 Feb 12. Epub 2019 Feb 12.

Department Psychology, Health and Technology, Faculty of Behavioral, Management and Social sciences, University of Twente, PO box 217, 7500 AE, Enschede, The Netherlands.

Objective: To evaluate ultrasonographic subclinical inflammatory synovitis and enthesitis in psoriasis patients, without clinical arthritis or enthesitis compared with healthy controls, with a 2-year follow-up to study the associated incidence of psoriatic arthritis (PsA).

Methods: A total of 109 consecutive psoriasis vulgaris patients without clinical signs of PsA and 90 healthy controls were included from two tertiary medical centers. Subjects underwent dermatological examination, PASI score evaluation for severity of psoriasis, musculoskeletal examination using 68/66 joints count for tenderness and swollen joints. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04445-0DOI Listing
February 2019
1 Read

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial.

Arthritis Rheumatol 2019 Feb 12. Epub 2019 Feb 12.

Amgen Inc, Thousand Oaks, CA, USA.

Objective: To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept in patients with psoriatic arthritis (PsA).

Methods: In this double-blind study, 851 PsA patients were randomized to: oral methotrexate 20mg plus placebo weekly (N=284), etanercept 50mg plus placebo weekly (N=284), or etanercept 50mg plus oral methotrexate 20mg weekly (combination therapy; N=283). American College of Rheumatology (ACR)20 response and Minimal Disease Activity (MDA) response at week 24 were the primary and key secondary endpoints, respectively. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/art.40851
Publisher Site
http://dx.doi.org/10.1002/art.40851DOI Listing
February 2019
4 Reads

The Relationship between HLA-B27, HLA-Cw06, HLA-DR7 and Psoriatic Arthritis in Vietnamese Patients: Disease Progression and Therapeutic Burden.

Open Access Maced J Med Sci 2019 Jan 27;7(2):300-301. Epub 2019 Jan 27.

University of Rome G. Marconi, Rome, Italy.

We conducted a prospective, cross-sectional study at Ho Chi Minh City Hospital of Dermato Venereology from January 2016 to March 2017 in 40 psoriatic arthritis (PsA) patients to evaluate the disease progression and therapeutic burden about the HLA patterns. Based upon our results, PsA with HLA-B27 (+) had a threat of severe arthritis. PsA with HLA-Cw06 (+) had a higher risk of earlier onset and shorter duration for plaque psoriasis to transform into PsA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364717PMC
January 2019
1 Read

Effectiveness, Safety and Tolerance of Methotrexate in Vietnamese Psoriatic Arthritis Patients.

Open Access Maced J Med Sci 2019 Jan 27;7(2):250-252. Epub 2019 Jan 27.

University of Rome G. Marconi, Rome, Italy.

Aim: To access the effectiveness, safety and tolerance of methotrexate (MTX) in psoriatic arthritis (PsA) treatment.

Methods: We recruit 37 patients, admitted at HCMC Hospital of Dermato-Venereology from 1/2016 to 3/2017, with MTX dosage ranging from 10 mg to 15 mg per week.

Results: Skin lesion response after 12 weeks improved PASI 50: 40. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364709PMC
January 2019
1 Read

Treating to Target(s) With Interleukin-17 Inhibitors.

J Cutan Med Surg 2019 Feb 11:1203475418824565. Epub 2019 Feb 11.

12 University of Alberta, Edmonton, AB, Canada.

Background:: The treat-to-target (T2T) strategy has become established in several medical specialties as a key guidance to optimal therapeutic decision making. T2T may be effective in the assessment of the biologic class of agents called interleukin (IL)-17 inhibitors, which are emerging as a safe and effective treatment option for autoimmune inflammatory conditions such as plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).

Objective:: The objective of this article is to use a T2T approach for the evaluation of the effectiveness and safety of IL-17 inhibitors in the management of patients with plaque psoriasis, PsA, and AS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418824565DOI Listing
February 2019
6 Reads

Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.

Nat Rev Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting 3% of the world's population, and approximately one-third of patients with psoriasis will eventually transition to having psoriatic arthritis (PsA). The evolution from cutaneous to synovio-entheseal inflammation in these patients presents an opportunity to investigate the critical events linked to arthritis development. The events responsible for progression to PsA are currently unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0175-0DOI Listing
February 2019
1 Read

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments.

RMD Open 2019 22;5(1):e000779. Epub 2019 Jan 22.

Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium.

Objectives: Psoriatic arthritis is a chronic inflammatory disease that affects the musculoskeletal system. It can include arthritis, spondylitis, dactylitis and enthesitis, and is strongly associated with the presence of psoriasis. The introduction of biological therapies as a treatment option has brought a significant improvement in disease control for patients with psoriatic arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000779DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347028PMC
January 2019
5 Reads

Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis.

Radiol Med 2019 Feb 9. Epub 2019 Feb 9.

Radiology Department, Università Politecnica delle Marche, Ancona, Italy.

Structural changes of bone and cartilage are the hallmarks of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Radiography can help in making diagnosis and in differentiating PsA and RA from other articular diseases. Radiography is still considered the preferred imaging method to assess disease progression, reflecting cumulative damage over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11547-019-01001-3DOI Listing
February 2019
6 Reads

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Drug Saf 2019 Feb 9. Epub 2019 Feb 9.

Department of Dermatology, University of Connecticut Health Center, 21 South Road, 2nd Floor, Farmington, CT, 06030, USA.

Introduction: Theoretical risks of biologic agents remain under study.

Objective: The aim of this study was to integrate 1-year safety data from 12 ustekinumab registrational trials.

Methods: Patients had moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA) (± methotrexate), or moderate-to-severe Crohn's disease (CD; failed/intolerant of immunomodulators/corticosteroids). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-019-00797-3DOI Listing
February 2019
2 Reads

Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and management.

Clin Immunol 2019 Feb 6. Epub 2019 Feb 6.

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory musculoskeletal condition with complex pathophysiology. In recent years, understanding of the pathogenesis of PsA has improved substantially. Several genetic and inflammatory factors have been identified and studied as targets for new biologic disease-modifying therapies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216616183067
Publisher Site
http://dx.doi.org/10.1016/j.clim.2019.02.001DOI Listing
February 2019
4 Reads

Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation.

J Eur Acad Dermatol Venereol 2019 Feb 8. Epub 2019 Feb 8.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Dermatology, Venerology und Allergy, Division of Evidence-Based Medicine (dEBM).

Twenty percent of patients with plaque psoriasis also have psoriatic arthritis - a disease affecting joints and entheses. Different treatment options exist but currently no succinct systematic overview exists. A systematic review of approved systemic treatments for psoriatic arthritis was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15482DOI Listing
February 2019
2 Reads

A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab - a new side effect after 15 years of usage.

BMC Infect Dis 2019 Feb 7;19(1):127. Epub 2019 Feb 7.

University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Mirogojska 8, 10000, Zagreb, Croatia.

Background: Tumor necrosis factor-α (TNF-α) antagonists, most of which are monoclonal antibodies, became a widespread treatment for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, psoriasis, psoriatic arthritis, hidradenitis suppurativa and uveitis. Their use is based on the blockage of TNF-α, which plays an important role in granulomas formation, development of phagosomes, activation and differentiation of macrophages, immune response against viral pathogens. The multiple adverse effects of TNF-α inhibition have been identified, including a two-to four-fold increased risk of active tuberculosis and other granulomatous conditions and an increased occurrence of some other serious bacterial, fungal and certain viral infections. Read More

View Article

Download full-text PDF

Source
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s128
Publisher Site
http://dx.doi.org/10.1186/s12879-019-3768-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367735PMC
February 2019
2 Reads

Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development.

Expert Rev Clin Immunol 2019 Feb 7:1-4. Epub 2019 Feb 7.

a Department of Rheumatology and Clinical Immunology , University Medical Center Utrecht , Utrecht , The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1580144DOI Listing
February 2019
1 Read

Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically-appraised topic.

Br J Dermatol 2019 Feb 6. Epub 2019 Feb 6.

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Clinical Question: Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis (PsA) in obese individuals?

Background: Obesity presents a rising public health challenge and is more prevalent amongst individuals with psoriasis or PsA compared to the general population. Longitudinal population-based studies suggest a causal role for obesity in psoriasis and PsA onset and that obesity drives greater disease severity.

Methods: We systematically reviewed evidence within Medline/EMBASE/CENTRAL databases and clinical trials registries examining lifestyle, pharmacological and surgical weight loss interventions in the treatment and prevention of psoriasis and PsA in obese individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17741DOI Listing
February 2019
4 Reads

Evaluation of subclinical gut inflammation using fecal calprotectin levels and colonic mucosal biopsy in psoriasis and psoriatic arthritis patients.

Br J Dermatol 2019 Feb 6. Epub 2019 Feb 6.

Gastroenterology, India.

Relationship between the joint disease and the gut inflammation has been established in axial spondyloarthritis(SpA). However this is not well established in Psoriatic arthritis(PsA). Our aim was to compare gut inflammation in psoriasis (PsO), PsA and irritable bowel syndrome(IBS) using fecal calprotectin assay which is a non-invasive tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17745DOI Listing
February 2019
1 Read

Factors Predicting Persistence of Biologic Drugs in Psoriasis: A Systematic Review and Meta-Analysis.

Br J Dermatol 2019 Feb 6. Epub 2019 Feb 6.

Division of Dermatology, Department of Medicine, University of Alberta, Alberta, Canada.

Background: Long-term therapy of psoriasis is impaired by gradual loss of effectiveness and treatment discontinuation. Identifying factors that affect biologic drug survival may help in treatment optimization.

Objectives: To identify factors that predicted biologic drug persistence or discontinuation in a real-life setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17738DOI Listing
February 2019
1 Read

AbbVie and J&J dominate clinical trial development in psoriatic arthritis, says GlobalData.

Authors:

Rheumatology (Oxford) 2019 Feb 5. Epub 2019 Feb 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez019DOI Listing
February 2019
1 Read

Lymphoprolipherative skin reactions induced by anti-TNFα: An open question.

J Dermatolog Treat 2019 Feb 6:1-14. Epub 2019 Feb 6.

a 1st Department of Dermatology "Andreas Syggros" Hospital, Medical School, National and Kapodistrian University of Athens , Athens , Greece.

Although anti-TNFα agents have revolutionized the treatment of many inflammatory diseases, various concerns have been reported regarding the risks of cancer development, as well as acceleration of the progression of subclinical, pre-existing malignancies. In this case series we investigated the provocative effect of anti-TNFα drugs in the development of cutaneous mycosis fungoides (MF)-like lymphoproliferative reactions. We describe 5 patients aged between 25-63 diagnosed with autoimmune disorders (psoriatic arthritis- one patient, Crohn's disease- one patient and ankylosing spondylitis- three patients) who received anti-TNFα agents before the development of a cutaneous lymphoproliferative reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1579889DOI Listing
February 2019
1 Read

[Anti-interleukin 17 is a new possible treatment of patients with psoriatic arthritis].

Ugeskr Laeger 2019 Jan;181(4)

Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with comorbidity and decreased quality of life. The current treatment of PsA is non-steroid anti-inflammatory drugs or in more severe cases disease modifying antirheumatic drugs such as methotrexate or leflunomide, but these agents are often inadequately effective. Biologic tumour necrosis factor (TNF)-inhibitors are effective in the treatment of PsA. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Clin Rheumatol 2019 Feb 4. Epub 2019 Feb 4.

Oregon Health & Science University, Portland, OR, USA.

Objective: There are limited data on therapy selection and switching in psoriatic arthritis (PsA). This 18 country, real-world study assessed use and switching of immunomodulatory therapy (biologic/apremilast), the extent of treatment failure and its association with reduced physical functioning, health-related quality of life (HRQoL), and work productivity and activity impairment (WPAI).

Methods: PsA patients under routine care and their treating physicians provided demographics, current therapy, reasons for switching, duration of first therapy, HRQoL, HAQ-DI, and WPAI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04446-zDOI Listing
February 2019
2 Reads

Efficacy of secukinumab in psoriasis and psoriatic arthritis: A retrospective multicentre study.

Med Clin (Barc) 2019 Feb 1. Epub 2019 Feb 1.

UGC Dermatología, Hospital Universitario Carlos Haya, Málaga, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2018.12.009DOI Listing
February 2019
1 Read

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

RMD Open 2019 11;5(1):e000808. Epub 2019 Jan 11.

Pfizer Inc, Groton, Connecticut, USA.

Objectives: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with inadequate responses to tumour necrosis factor inhibitors (TNFi-IR) in a 6-month, phase III randomised controlled trial (OPAL Beyond [NCT01882439]).

Methods: Patients (N=394) received tofacitinib 5 or 10 mg twice daily or placebo (advancing to tofacitinib 5 or 10 mg twice daily at month 3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340607PMC
January 2019
3 Reads

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

RMD Open 2019 11;5(1):e000806. Epub 2019 Jan 11.

Pfizer Inc, Groton, Connecticut, USA.

Objectives: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïve in a 12-month, phase III randomised controlled trial (OPAL Broaden [NCT01877668]).

Methods: Patients (N=422) received tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg subcutaneously every 2 weeks or placebo advancing to tofacitinib 5 mg or 10 mg twice daily at month 3. Read More

View Article

Download full-text PDF

Source
http://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2018-00080
Publisher Site
http://dx.doi.org/10.1136/rmdopen-2018-000806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340575PMC
January 2019
10 Reads

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.

RMD Open 2019 11;5(1):e000585. Epub 2019 Jan 11.

Institute of Pharmaceutical Science, King's College London, London, UK.

Objective: This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) to develop adherence prediction models.

Methods: The population was a subset from ALIGN, a multicountry, cross-sectional, self-administered survey study in adult patients (n=7328) with six immune-mediated inflammatory diseases who were routinely receiving systemic therapy. Instruments included Beliefs about Medicines Questionnaire (BMQ) and 4-item Morisky Medication Adherence Scale (MMAS-4), which was used to define adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2017-000585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340591PMC
January 2019
1 Read

Rapid spread of mannan to the immune system, skin and joints within six hours after local exposure.

Clin Exp Immunol 2019 Feb 3. Epub 2019 Feb 3.

Medical Inflammation Research, MediCity Research Laboratory, University of Turku, FI-20520, Turku, Finland.

Psoriasis (Ps), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are common diseases dependent on environmental factors that activate the immune system in unknown ways. Mannan is a group of polysaccharides common in the environment; they are potentially pathogenic because at least some of them induce Ps-, PsA- and RA-like inflammation in mice. Here, we used positron emission tomography/computed tomography to examine in vivo transport and spread of mannan labelled with F. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cei.13268DOI Listing
February 2019
2 Reads

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Ann Rheum Dis 2019 Feb 2. Epub 2019 Feb 2.

Swedish Medical Center, University of Washington, Seattle, Washington, USA.

To develop a comprehensive listing of the greatest unmet scientific and clinical needs in rheumatology. The 20th annual international Targeted Therapies meeting brought more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of five disease-specific groups with 20-30 experts assigned to each group based on expertise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214280DOI Listing
February 2019
5 Reads

Peritenon extensor tendon inflammation in Psoriatic Arthritis is an enthesitis-related lesion.

J Rheumatol 2019 02 1. Epub 2019 Feb 1.

From the Department of Rheumatology, Hospital Universitario Severo Ochoa. Madrid. Spain; Department of Rheumatology. Chronic Diseases Study Center (CEDOC), NOVA Medical School, UNL; HEM. Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa, Portugal; Division of Musculoskeletal and Rheumatic Disorders. Instituto Nacional de Rehabilitación. Mexico City, Mexico; Department of Rheumatology. Hospital Clínico Universitario. Valladolid. Spain; Department of Rheumatology. Diakonhjemmet Hospital, Oslo, Norway; Department of Rheumatology. Hospital Universitario La Paz. Madrid. Spain. Address correspondence to Cristina Macía Villa, Rheumatologist MD. Department of Rheumatology. Hospital Universitario Severo Ochoa. Av. de Orellana, s/n, 28911 Leganés, Madrid, Spain. Email

Objective: To analyse the association between enthesitis, synovitis and peritenon extensor tendon inflammation (PTI) in Psoriatic Arthritis (PsA).

Methods: PsA patients with swelling of metacarpophalangeal joints were included. Grey scale (GS) and power Doppler (PD) were used for synovitis and PTI ultrasound identification. Read More

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.180856
Publisher Site
http://dx.doi.org/10.3899/jrheum.180856DOI Listing
February 2019
3 Reads